PEN

Penumbra
NYSE

Real-time Quotes | Nasdaq Last Sale

194.18
+0.79
+0.41%
After Hours: 194.18 0 0.00% 16:22 09/25 EDT
OPEN
192.68
PREV CLOSE
193.39
HIGH
195.25
LOW
187.43
VOLUME
332.55K
TURNOVER
--
52 WEEK HIGH
241.81
52 WEEK LOW
121.80
MARKET CAP
7.01B
P/E (TTM)
1578.70
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Best And Worst Large-Cap Stocks To Buy
Our overbought signal is improving, making it time to buy large-cap stocks.Here are the strongest and weakest large-cap sectors and industries to focus your attention on.The best and worst large-cap stocks include Black Knight, FactSet, and Alexion Pharmaceuticals.
Seekingalpha · 10h ago
Checks have BofA staying bullish on medtech names as demand shores up
A couple of weeks of diligence calls has led to an update on medical technology from BofA, where it changes a few ratings (mainly on valuation), raises a few price
Seekingalpha · 09/08 23:30
Penumbra, Inc. to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Morgan Stanley 18th Annual Global Healthcare Conference on Thursday, September 17, 2020.
PR Newswire · 09/03 21:05
Penumbra, Inc. to Present at the Wells Fargo 2020 Virtual Healthcare Conference
Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Wells Fargo 2020 Virtual Healthcare Conference on Wednesday, September 9, 2020.
PR Newswire · 08/26 21:05
Why I'm Worrying Over A Market Drop
Our overbought indicator reaches rarefied air.It could be a good time to rein in risk by reducing margin and avoiding short-term calls.The top stocks to add to buy if the market drops.
Seekingalpha · 08/17 20:22
The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 12:18
Citigroup Maintains Buy on Penumbra, Raises Price Target to $264
Citigroup maintains Penumbra (NYSE:PEN) with a Buy and raises the price target from $214 to $264.
Benzinga · 08/04 14:50
Penumbra stock price target raised to $245 from $200 at Canaccord Genuity
marketwatch.com · 08/04 09:48
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PEN. Analyze the recent business situations of Penumbra through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PEN stock price target is 252.80 with a high estimate of 264.00 and a low estimate of 245.00.
EPS
Institutional Holdings
Institutions: 224
Institutional Holdings: 30.74M
% Owned: 85.13%
Shares Outstanding: 36.11M
TypeInstitutionsShares
Increased
76
2.24M
New
50
815.34K
Decreased
53
2.37M
Sold Out
32
508.67K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.16%
Healthcare Equipment & Supplies
+2.01%
Key Executives
Chairman/Chief Executive Officer/Director
Adam Elsesser
Chief Financial Officer
Maggie Yuen
Corporate Executive
James Pray
Executive Vice President/General Counsel/Secretary
Johanna Roberts
Executive Vice President
Lynn Rothman
Chief Accounting Officer
Lambert Shiu
Other/Director
Arani Bose
Independent Director
Harpreet Grewal
Independent Director
Don Kassing
Independent Director
Janet Leeds
Independent Director
Bridget O'Rourke
Independent Director
Surbhi Sarna
Independent Director
Thomas Wilder
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PEN
Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Penumbra Inc stock information, including NYSE:PEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PEN stock methods without spending real money on the virtual paper trading platform.